Moreover, elevated CD8+ and low Forkhead box protein 3 positive (FOXP3+) T-cell infiltrates have been identified to serve as an independent predictor of improved OS and RFS after treatment with neoadjuvant chemotherapy in patients with HER2-positive and HER2-negative breast cancer [55]. The gene discussed is CD8A; the disease is breast cancer.